HAPPENING NOW
The headlines, minus the noise. Updated in real time. Beta
STAT+: FDA wants to exclude weight loss drugs from a compounding list
FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.
AI Summary Powered by HappeningNow
FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.
AI summaries can be wrong sometimes—always verify important details using the source link below.
Category Health
Outlet Statnews
Source statnews.com